Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation
Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Michael Krause(Fahrenheit (Germany)), Axel Millahn(Philipps University of Marburg), Thomas Illmer(Center for Systems Biology Dresden), Christina Barckhausen(Philipps University of Marburg), Petra Ross(Universitätsklinikum Gießen und Marburg), Thorsten Stiewe(Philipps University of Marburg), Marco Mernberger(Philipps University of Marburg), Kathleen Stabla(Universitätsklinikum Gießen und Marburg), Minh Huynh(Philipps University of Marburg), Sabine Teichler(Philipps University of Marburg)
Cited by 10
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Online Parallel Accumulation–Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer
|Molecular & Cellular Proteomics|2018|1k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573